2007 News

  • The Swiss Institute for Vaccine Research, a new initiative aligned with the scientific strategic plan of the Enterprise is launched December 5, 2007 in Lausanne, Switzerland.

  • A summary report from the Enterprise workshop titled “Antibody-Based HIV-1 Vaccine: Recent Developments and Future Directions,” is published in the December 2007 edition of PLoS Medicine.

  • Update on the STEP and Phambili studies of a Merck vaccine candidate

  • Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat.

  • Merck and the HIV Vaccine Trials Network (HVTN) announce discontinuation of vaccinations and enrollment for the STEP study after an interim analysis showed the vaccine was not effective.

  • The AIDS Vaccine 2007 conference takes place August 20-23 in Seattle, Washington

  • The AIDS Vaccine Advocacy Coalition (AVAC) releases its 2007 report, entitled “Resetting the Clock”

  • A study conducted by the US NIH's Center for HIV/AIDS Vaccine Immunology (CHAVI) has yielded a new understanding of why some people can suppress virus levels following HIV infection.

  • Canada's Government and the Bill & Melinda Gates Foundation have committed major new funding to support the Canadian HIV Vaccine Initiative.

  • The European and Developing Countries Clinical Trials Partnership (EDCTP) and the Bill & Melinda Gates Foundation launch a 20 M Euro call to develop HIV vaccine trial capacity in Africa.

All Content ©2005 - 2008 Global HIV Vaccine Enterprise